Format

Send to

Choose Destination
Mult Scler Int. 2012;2012:935921. doi: 10.1155/2012/935921. Epub 2012 Aug 15.

Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.

Author information

1
Division of Neurology, CSSSG-Hull Pavillion, Clinique Neuro-Outaouais, 147 Boulevard d'Europe, Gatineau, QC, Canada J9J A05.

Abstract

Tacrolimus is a calcineurin inhibitor which works to induce immune suppression by preventing cytokine transcription and lymphocyte activation. Combining the immunomodulator interferon beta-1b (Betaseron) with the immunosuppressant tacrolimus (Prograf) may have the potential of additive therapeutic benefit through the complementary mechanisms of action of these two therapeutics. In this randomized, open-label, multicenter, two-arm pilot study, the authors examined the safety and tolerability of the combination of interferon beta-1b and tacrolimus in relapsing remitting (RRMS) and secondary progressive (SPMS) multiple sclerosis patients who have failed one or more immunomodulatory therapies. Patients (n = 25) received a combination of interferon beta-1b subcutaneously every other day and oral tacrolimus (low blood level tacrolimus, 1-5‚ÄČng/mL, or high blood level tacrolimus, 5-10‚ÄČng/mL) for a period of 38 weeks. The combination therapy of interferon beta-1b and tacrolimus over the 10-month period of the study was shown to be safe and relatively well tolerated. There were no unexpected adverse events occurring as the result of the combination therapy. Further study of this combination therapy in patients with multiple sclerosis unresponsive to conventional therapy is warranted.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center